Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.

摘要: Objectives: To evaluate the efficacy and safety of weekly administration gemcitabine treatment in chemotherapy-naive patients with advanced biliary tract gallbladder cancer. Patients methods: Gemcitabine at a dose 800 mg/m2 was administered as 30-min infusion to previously operated, histologically confirmed, metastatic, or unresectable locally cholangiocarcinoma. Treatment continued until unacceptable toxicity disease progression. Results: A total 30 (median age 66 years; range 54–72 years) were included study. median 14 (range, 4–33) doses administered. Out evaluable for response, nine partial responses observed (30.0%), while further 11 demonstrated stable (36.7%). The time progression 7 months 5–34). Overall response rate superior cancer (ORR=35.7%) compared those duct (ORR=27.3%). This correlated significantly longer 6.4 (95% confidence interval (CI), 5.6–7.1 months) versus 3.6 CI, 2.9–4.3 months; p=0.03) better overall survival 17.1 15.8–18.5 11.4 10.2–12.6 months, p=0.021). Toxicities generally mild only one case grade 3 neutropenia. There no cases febrile neutropenia treatment-related deaths. Conclusions: Weekly provides safe, well-tolerated, effective chemotherapy naive cholangiocarcinoma, particularly origin.